Molnlycke Health Care

Two Omega Drive, Irlam, Manchester, M44 5BJ , UK
Telephone: +44 (0)161 777 2600
Fax: +44 (0)161 777 2601
WWW: http://www.molnlycke.com
Medical Information Direct Line: +44 (0)161 777 2628
Medical Information e-mail: ukmedical.information@molnlycke.com
Customer Care direct line: +44 (0)161 777 2600
Medical Information Fax: +44 (0)161 621 2045


Summary of Product Characteristics last updated on the eMC: 20/09/2006
SPC Betadine Dry Powder Spray


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Betadine Dry Powder Spray.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Povidone Iodine 2.5% w/w.


Go to top of the page
3. PHARMACEUTICAL FORM

Pressurised aerosol spray.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Antiseptic for the treatment and prevention of infection in wounds including ulcers, burns, cuts and other minor injuries.


Go to top of the page
4.2 Posology and method of administration

For topical use only. Adults and children aged 2 years and over: Shake the can well before use. Spray the required area from a distance of 15-25cm (6-10 inches) until a dusting of powder is deposited. If necessary, the treated area may be covered with a dressing.


Go to top of the page
4.3 Contraindications

Hypersensitivity to iodine. Betadine Dry Powder Spray should not be used in serous cavities. Do not use this product regularly if the patient suffers from thyroid disorders or is receiving concurrent lithium therapy. Do not use on children under two years of age.


Go to top of the page
4.4 Special warnings and precautions for use

Avoid inhaling or spraying into the eyes. Avoid use on patients with renal impairment. Should evidence of local irritation or sensitivity occur, use of the product should cease. If no improvement occurs, a doctor should be consulted.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Use with concurrent lithium therapy has been shown to exhibit additive hypothyroidic effects.


Go to top of the page
4.6 Pregnancy and lactation

Use in pregnancy or lactation should be limited. Although no adverse effects are anticipated from such limited usage, caution is recommended and therapeutic benefit must be balanced against the possible effects of the absorption of iodine on foetal thyroid function and development.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Iodine is absorbed through burns and broken skin and to a lesser extent through intact skin. Following prolonged application of Betadine Dry Powder Spray to severe burns or large areas of denuded skin, systemic effects such as metabolic acidosis, parametrical renal impairment and thyroid dysfunction may occur.


Go to top of the page
4.9 Overdose

Excess iodine can produce goitre and hypothyroidism or hyperthyroidism. Systemic absorption of iodine after repeated application of povidone iodine to large areas of wounds or burns may lead to a number of adverse effects: metallic taste in mouth, increased salivation, burning or pain in the throat or mouth, irritation and swelling of the eyes, pulmonary oedema, skin reactions, gastrointestinal upset and diarrhoea, metabolic acidosis, hypernatraemia and renal impairment.

Treatment: In the case of deliberate or accidental ingestion of large quantities of Betadine, symptomatic and supportive treatment should be provided with special attention to electrolyte balance and renal and thyroid function.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Povidone iodine is a complex of iodine which retains the broad-spectrum germicidal activity of the elemental iodine without its disadvantages. The germicidal activity is maintained in the presence of blood, pus, serum and necrotic tissue.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Isopropyl myristate; n-pentane; butane 40; soya lecithin.


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

36 months unopened.


Go to top of the page
6.4 Special precautions for storage

Store at or below 25oC.


Go to top of the page
6.5 Nature and contents of container

Aerosol cans containing 100ml of product.


Go to top of the page
6.6 Special precautions for disposal and other handling

None.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Medlock Medical Limited, Tubiton House, Medlock Street, Oldham, OL1 3HS.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 21248/0005.


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

19th April 2006.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

April 2006.



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/1953/SPC/


Active Ingredients/Generics

 
   povidone iodine